As per the report, the size of the North American nuclear medicine market is estimated at USD 2.48 billion in 2021 and is expected to reach USD 4.22 billion by 2026, growing at a CAGR of 11.2%.
Nuclear medicine has seen several technological advances, with applications ranging from diagnostics to therapy. In recent years, several technological advances in nuclear diagnostic imaging have led to significant ease in diagnosing, treating, and managing chronic and critical disorders.
Nuclear medicine has an immense role in treating chronic and cardiovascular diseases, setting up growth opportunities for North America. These nuclear medicines are more applicable to ensure patient safety while utilizing medical mobility equipment, hospital beds, lift chair positions, power wheelchairs, and mobility scooters. It is also ascribed to outshine the demand of the market to the extent. Furthermore, the market is propelled by rising investments in end-users by private and public organizations.
The growth of the market can mainly be attributed to the increase in the incidence and prevalence of cancer and heart disease and initiatives to reduce the gap between the supply and demand of Mo-99. One of the critical drivers for the Nuclear Medicine Imaging market's growth is raising awareness about the potential impact of early and timely diagnosis and the corresponding positive impact on the management and treatment of chronic disorders. In particular, PET / PET-CT advances in nuclear imaging technology have helped extend the applications of this modality beyond oncology to cardiology, neurology, and infection detection. There has been a substantial increase in the volume of PET and SPECT procedures due to these technological advancements. For example, further improvements, such as the development of cadmium-zinc telluride (CZT) -based detectors, which facilitate simultaneous visualization of physiological and anatomical structures, are expected to drive the adoption of SPECT-CT systems. New product launches in radiopharmaceuticals and the strong and robust portfolio of several key market players are other critical factors. The increasing demand for nuclear imaging has led to new product initiation and robust pipelines for diagnostic radiopharmaceuticals. Due to the high prevalence of cancer and the wide application of nuclear medicine imaging in its diagnosis, several product launches have been targeted in different oncology applications.
The short half-life of radiopharmaceuticals reduces their potential adoption. Simultaneously, hospital budget cuts and high equipment prices have made it difficult for some end-users to rely on nuclear medicine. These factors are expected to hamper the growth of the nuclear medicine market during the forecast period.
This research report on the North America Nuclear Medicine Market has been segmented and sub-segmented into the following categories:
By Type:
By Application:
By Country:
Geographically, North America is holding the highest shares of the market with the rising hospitals and diagnostics centers' rising construction. Growing capital income in both developed and developing countries are escalating the shares of the market. The U.S. is accounted for the leading position for the past few years by increasing focus on alternative treatment procedures, especially with nuclear medicines. Canada follows the U.S in holding the highest shares of the market with the rise in support from the government through funds in hospitals' construction with advanced technologies. The increase in the production rate of various drugs in the radiopharmaceuticals is leveraging this market demand in North America.
In 2020, the US region dominated the North American nuclear medicine/radiopharmaceutical market in terms of revenue, with a market share of 54% due to advanced treatments, innovative products, and favorable government reimbursement policies in this country. This growth can be attributed to increased research and development initiatives and government support for improving the health sector. According to the Society for Nuclear Medicine/Radiopharmaceuticals, 21 million nuclear medicine procedures using radiopharmaceuticals and imaging instruments are executed each year in hospitals in the United States to diagnose the disease. They provide targeted treatments, which are the main contributors to the North American Nuclear Medicine/radiopharmaceutical market's disease growth. Canada is expected to register the fastest growth rate during the forecast period 2020-2025.
Promising companies leading the North America Nuclear Medicine Market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc., and IBA Molecular Imaging.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Diagnostic Radioisotopes
5.1.1.1 SPECT
5.1.1.1.1 Technetium-99m
5.1.1.1.2 Thallium-201
5.1.1.1.3 Gallium-67
5.1.1.1.4 Iodine-23
5.1.1.1.5 Others
5.1.1.2 PET
5.1.1.2.1 Fluorine-18
5.1.1.2.2 Rubidium-82
5.1.1.2.3 Others
5.1.2 Therapeutic Radioisotopes
5.1.2.1 Beta Emitters
5.1.2.1.1 Iodine-131
5.1.2.1.2 Yttrium-90
5.1.2.1.3 Samarium-153
5.1.2.1.4 Rhenium-186
5.1.2.1.5 Lutetium-177
5.1.2.2 Alpha Emitters
5.1.2.2.1 Radium-223
5.1.2.3 Brachytherapy
5.1.2.3.1 Cesium-131
5.1.2.3.2 Iodine-125
5.1.2.3.3 Palladium-103
5.1.2.3.4 Iridium-192
5.2 By Application
5.2.1 Cardiology
5.2.2 Lymphoma
5.2.3 Thyroid
5.2.4 Neurology
5.2.5 Oncology
5.2.6 Others
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Hologic Inc.
8.3 Segami Corporation
8.4 Positron Corporation
8.5 Bracco Imaging S.P.A
8.6 Naviscan Inc.
8.7 Bayer Healthcare
8.8 Lantheus Medical Imaging Inc.
8.9 IBA Molecular Imaging
8.10 Medix Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
